In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
UK utility extracting glucose from used TP
In the United Kingdom, water treatment company United Utilities is trialing a process at its Blackburn sewage works to extract glucose from used toilet...
Stella McCartney takes flight with plant-based feathers
In New York, sustainability-focused designer Stella McCartney used faux feathers made from plant-based materials in fashions exhibited at the recent Paris Fashion Week.
Produced...
Artificial Nature hits milestone scaling PLH
In Germany, Artificial Nature S.L. has scaled up production of its biobased and biodegradable copolyester PLH to 300 metric tons per year. The milestone...